报价延迟最少15分钟:2026/07/19 11:30 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.79 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-12.64/-0.24
|
|
企业价值
3.41M
|
| 资产负债 |
|
每股账面净值
9.51
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
12.42K
|
|
每股收益
0.01
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications. |
